Skip to main content
OpenTrials
Completed

NCT Number: NCT05446493

Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction

The aim of this current study is to estimate serum level of YKL-40, serum total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Erectile Dysfunction Erectile Dysfunction With Diabetes Mellitus Genital Diseases Genital Diseases, Male Male Urogenital Diseases Mental Disorders Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Urogenital Diseases

Age range

30 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Aswan university

Aswān, 81528, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diabetic patients with ED.

Exclusion criteria

  • Patients with history of pelvic trauma.
  • Patients with major pelvic surgical intervention.
  • Patients with hypogonadism and hyperprolactinemia.
  • Patients with chronic liver disease.
  • Patients with cardio vascular system diseases.
  • History of chronic intake of central nervous system, anti androgen drugs or other drugs as Tramadol.
  • Smokers patients.
  • Patients with non-vasculogenic Erectile dysfunction.

Treatment and study plan

Tadalafil 5mg

Drug
  • Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.
  • Penile color Doppler ultrasound examination before and after treatment

Primary outcomes

  1. Serum YKL-40 and platelets indices in erectile dysfunction

    Time frame: 3 months

    Measurement of YKL-40 and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil.

Secondary outcomes

  1. Effect of tadalafil on Erectile dysfucntion patients

    Time frame: 3 months

    To show the therapeutic effect of tadalafil in dose 5 mg daily on Erectile dysfucntion patients and assess their response by international index of erectile function (IIEF-5)

Sponsors and collaborators

Lead sponsor

Aswan University

Other

Registry information

Official study title

Assessment of Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Jul 6, 2022
Registry last updated
Jul 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.